Evidence map›Paper›PMID 37533438›Full record

ArticleJTO clinical and research reports2023

Pretreated

Corrado Orciuolo, Federico Cappuzzo, Lorenza Landi, Blerina Resuli, Silvia Carpano, Antonello Vidiri, Simonetta Buglioni, Chiara Mandoj, Gennaro Ciliberto, Gabriele Minuti

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Corrado OrciuoloDivision of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Federico CappuzzoDivision of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Lorenza LandiClinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Blerina ResuliDivision of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Silvia CarpanoDivision of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Antonello VidiriIRCCS Regina Elena National Cancer Institute, Rome, Italy.
Simonetta BuglioniIRCCS Regina Elena National Cancer Institute, Rome, Italy.
Chiara MandojIRCCS Regina Elena National Cancer Institute, Rome, Italy.
Gennaro CilibertoIRCCS Regina Elena National Cancer Institute, Rome, Italy.
Gabriele MinutiClinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated

Indexed as

Case reportNSCLCOsimertinibResistanceTargeted therapy

Identifiers

PMID37533438
PMCPMC10392131
OpenAlexW4382651838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.